• Forum
  • Aktiemarkeder
    • MarkederRealtidskurser, indekser og markedsudvikling
    • BørskalenderKommende resultater, noteringer og virksomhedsbegivenheder
    • UdbyttekalenderKommende og tidligere udbytter
  • Selskaber
    • SelskaberGennemse og filtrer den fulde liste over børsnoterede selskaber
    • OpdagInspiration til din næste investering
    • BørsnoteringerNye noteringer og kommende børsintroduktioner
    • Invitationer til generalforsamlingerDatoer for generalforsamlinger og aktionærinformation
  • Aktieanalyse
    • ResearchEkspertaktieanalyse og anbefalinger
    • ArtiklerNyheder, indsigter og markedskommentarer
    • inderesTVVideocenter for aktieanalyse, forskning og ekspertkommentarer
    • TransskriptionerFuldstændige udskrifter af resultatopkald og investormøder
    • AktieoversigtSammenlign nøgletal og udvikling på tværs af flere aktier
Find os på de sociale medier
  • Inderes Forum
  • Youtube
  • Facebook
  • X (Twitter)
Tag kontakt
  • info@hcandersencapital.dk
  • Bredgade 23B, 2. sal
    1260 København K
Inderes
  • Om os
  • Vores team
  • Karriere
  • Inderes som en investering
  • Tjenester for børsnoterede virksomheder
Vores platform
  • FAQ
  • Servicevilkår
  • Privatlivspolitik
  • Disclaimer

Inderes’ ansvarsfraskrivelse kan findes her. Detaljeret information om hver aktie, der aktivt overvåges af Inderes og HC Andersen Capital, er tilgængelig på de virksomhedsspecifikke sider på Inderes' hjemmeside. © Inderes Oyj. All rights reserved.

Bio-Works Technologies

3,63 SEK

-7,63 %

Mindre end 1K følgere

BIOWKS

Spotlight Stock Market

Biotechnology & Pharmaceuticals

Health Care

Oversigt
Finansielt overblik og estimater
Ejerskab
Dividend
Investorkonsensus
Sammenligne
-7,63 %
+15,61 %
+14,51 %
+38,55 %
+59,21 %
+98,36 %
-61,27 %
-69,69 %
-57,76 %

Bio-Works Technologies operates in biotechnology. The company develops products that separate and purify molecules in the production of pharmaceuticals. The technology is based on chromatography, which is intended to handle the drug substance. Customers are found in the European market where the products are sold via distribution partners and to companies in the pharmaceutical industry, as well as research institutes and universities. The company was founded in 2006 and has its headquarters in Uppsala.

Læs mere
Markedsværdi
363,04 mio. SEK
Aktieomsætning
134,9 t SEK
Omsætning
62,5 mio.
EBIT %
-28,03 %
P/E
-
Udbytteafkast, %
-
Omsætning og EBIT-margin
EPS og udbytte
Finanskalender
21.8
2026

Delårsrapport Q2'26

6.11
2026

Delårsrapport Q3'26

19.2
2027

Årsrapport '26

Alle
Selskabsmeddelelser
ViserAlle indholdstyper

Omsætning og EBIT-margin

Omsætning mio.

EBIT-% (adj.)

EPS og udbytte

EPS (adj.)

Udbytte %

Selskabsmeddelelse4.6.2026, 08.20

Bio-Works Technologies AB: Resolutions passed at Bio-Works Technologies' annual general meeting 2026

Bio-Works Technologies
Selskabsmeddelelse13.5.2026, 06.00

Bio-Works Technologies AB: Bio-Works reports first quarter 2026

Bio-Works Technologies
Selskabsmeddelelse29.4.2026, 13.17

Bio-Works Technologies AB: Bio-Works receives order for WorkBeads 40S from contract manufacturer in Europe

Bio-Works Technologies

Bliv en del af Inderes community

Gå ikke glip af noget - opret en konto og få alle de mulige fordele

Inderes konto
Følgere og notifikationer om fulgte virksomheder
Analytikerkommentarer og anbefalinger
Værktøj til at sammenligne aktier og andre populære værktøjer
Opret konto
Selskabsmeddelelse17.4.2026, 12.00

Bio-Works Technologies AB announces outcome from exercise of warrants of series TO 2. Exercise period 6 of 11

Bio-Works Technologies
Selskabsmeddelelse10.4.2026, 06.00

Bio-Works Technologies AB: Proposed New Board Members in Bio-Works

Bio-Works Technologies
Selskabsmeddelelse1.4.2026, 06.00

Today is the first day of the sixth exercise period for Bio-Works Technologies AB's warrants of series TO 2

Bio-Works Technologies
Selskabsmeddelelse1.4.2026, 06.00

Bio-Works Technologies AB - Business Update first quarter 2026

Bio-Works Technologies
Pressemeddelelse13.3.2026, 12.29

Redeye: Bio-Works (Intervju): Verksamhetsuppdatering

Bio-Works Technologies
Selskabsmeddelelse6.3.2026, 13.00

Bio-Works Technologies AB publishes Business Update ahead of next value creation phase

Bio-Works Technologies
Selskabsmeddelelse20.2.2026, 07.00

Bio-Works Technologies AB: Bio-Works publishes Year-end report Q4 2025

Bio-Works Technologies
Selskabsmeddelelse17.2.2026, 13.29

Bio-Works Technologies AB: Bio-Works Receives Order from Returning Customer

Bio-Works Technologies
Selskabsmeddelelse19.1.2026, 11.30

Bio-Works Technologies AB announces outcome from exercise of warrants of series TO 2. Exercise period 5 of 11

Bio-Works Technologies
Selskabsmeddelelse2.1.2026, 07.00

Today is the first day of the fifth exercise period for Bio-Works Technologies AB's warrants of series TO 2

Bio-Works Technologies
Selskabsmeddelelse2.1.2026, 06.00

Bio-Works Technologies AB: Business Update

Bio-Works Technologies
Selskabsmeddelelse29.12.2025, 07.00

Bio-Works Technologies AB: Bio-Works Receives Two WorkBeads 100S and 100Q Orders Worth SEK 4 Million

Bio-Works Technologies
Selskabsmeddelelse15.12.2025, 15.00

Bio-Works Technologies AB Annual General Meeting to be held on Thursday 4 of June 2026

Bio-Works Technologies
Selskabsmeddelelse7.11.2025, 07.00

Bio-Works Technologies AB: Bio-Works reports third quarter 2025

Bio-Works Technologies
Selskabsmeddelelse6.11.2025, 07.55

Bio-Works Technologies AB: Bio-Works receives order for WorkBeads 40S from contract manufacturer in Europe

Bio-Works Technologies
Pressemeddelelse29.10.2025, 11.00

Bio-Works Technologies AB: Bio-Works forms strategic partnership with Zenmindes Biotechnology to strengthen presence in China

Bio-Works Technologies
Selskabsmeddelelse21.10.2025, 08.00

Bio-Works Technologies AB: Bio-Works two largest shareholders, members of the board and the CEO have all exercised all their Warrants TO2

Bio-Works Technologies